I'm waiting on data breakout from longhaulers and cancer. Preliminary from longhaulers looks excellent. The two true data points median overall survival and median progression free survival will beat Trodlevy and none of the side effects. Doctors of course prefer not to deal with side effects so that gives leronlimab the edge.

With the suboptimal dosing it will be interesting to see the results from phase 2 with full 700mg doses.